Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 5.9% in August

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 4,300,000 shares, an increase of 5.9% from the August 15th total of 4,060,000 shares. Based on an average daily volume of 267,200 shares, the short-interest ratio is presently 16.1 days. Currently, 21.4% of the shares of the company are short sold.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DNTH. SG Americas Securities LLC acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $112,000. The Manufacturers Life Insurance Company acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $236,000. WINTON GROUP Ltd acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $265,000. Point72 DIFC Ltd acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $334,000. Finally, Virtu Financial LLC acquired a new position in shares of Dianthus Therapeutics in the 1st quarter valued at about $390,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded down $0.43 during mid-day trading on Tuesday, hitting $25.99. 189,056 shares of the stock traded hands, compared to its average volume of 186,213. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77. The company has a market cap of $762.81 million, a PE ratio of -4.46 and a beta of 1.85. The firm has a 50 day simple moving average of $28.12 and a two-hundred day simple moving average of $26.11.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The firm had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. On average, equities research analysts anticipate that Dianthus Therapeutics will post -2.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on DNTH shares. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Cantor Fitzgerald started coverage on Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating on the stock. Robert W. Baird started coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 price objective on the stock. Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, August 12th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $44.71.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.